GI
IKT icon

GAMMA Investing’s Inhibikase Therapeutics IKT Stock Holding History

GAMMA Investing’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-411
Closed -$690 – 4190
2026
Q1 		$690 Buy
+411
New +$730 ﹤0.01% 3901

Other funds holding IKT

PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GAMMA Investing's IKT Position: Q2 2026 in Review

GAMMA Investing sold out of Inhibikase Therapeutics (IKT) in Q2 2026, closing a stake of 411 shares — an estimated $690 sold.

GAMMA Investing first reported a position in IKT in Q1 2026 and held it in 1 quarter. The position peaked at $690 in Q1 2026. 6 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • GAMMA Investing reported no remaining Inhibikase Therapeutics position as of Q2 2026 after selling out during the quarter.
  • GAMMA Investing sold 411 Inhibikase Therapeutics shares in Q2 2026, an estimated $690.
  • GAMMA Investing first reported a position in Inhibikase Therapeutics in Q1 2026 and held it in 1 quarter.
  • GAMMA Investing's Inhibikase Therapeutics position peaked at $690 in Q1 2026.
  • 6 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.